Jan 6 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL-MYERS SQUIBB CO -PRELIMINARY ESTIMATED Q4 IMPACT OF ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT AND LICENSING LOSS OF $18 MILLION
Source text: [ID:]
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))